Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Alsius goes public via Ithaka buy-out: Privately held maker of CoolGard catheter-based intravascular temperature control systems for critical care patients plans to go public via a merger with investment vehicle Ithaka Acquisition Corp., announced Oct. 4. The deal is potentially worth about $77 mil., with Alsius receiving about $44 mil. in Ithaka stock up front and up to $33 mil. worth of additional stock, contingent upon certain performance milestones, Ithaka says. Publicly traded Ithaka was formed in 2005 to "effect a business combination with an operating business in the healthcare industry," the firm explains. Ithaka will change its name to Alsius when the deal closes. Alsius' CoolGard, the worldwide market leader in intravascular cooling, is 510(k)-cleared for normothermia maintenance in cardiac surgery patients, inducement of hypothermia in neurosurgery patients, and for fever reduction in patients with cerebral infarction and intracerebral hemorrhage. The firm also seeks expanded clearance to induce hypothermia to aid cardiac arrest patients (1"The Gray Sheet" March 21, 2005, p. 5). Ithaka's resources, including $48.5 mil. in cash, will help Alsius "accelerate market development and maintain market leadership," Ithaka says. Alsius generated $2.2 mil. in sales for the first six months of 2006, up 60% from the same period last year...

You may also be interested in...

Litigation In Brief

Diomed patent case proceeds to trial: U.S. District Court for Massachusetts finds that Diomed's patent on endovascular laser treatment for varicose veins is valid and enforceable. In a sealed order, dated Aug. 30, the Massachusetts court grants Diomed's motion for summary judgment, rejecting the patent invalidity claims by AngioDynamics and Vascular Solutions. The ruling relates to Diomed's patent on its EndoVenous Laser Treatment, which it acquired in 2003. The firm brought charges in 2004 against AngioDynamics (VenaCure) and Vascular Solutions (Vari-Lase) seeking injunctive relief and damages for alleged infringement. With the validity issue decided, Diomed is cleared to proceed to trial, expected to commence in 2007. The defendants hold that the decision is not a determination of whether patent infringement has actually occurred...

Alsius Tries To Warm FDA Panel To CoolGard 510(k), Gets Chilly Response

FDA should see convincing data from a three-arm, randomized controlled trial before granting 510(k) clearance to Alsius' CoolGard 3000 heat-exchange catheter system, Circulatory System Devices Panel members suggested March 17

Epoch Turn At Nanogen? Firm Grows ASR Menu With Stock-Swap Merger

Nanogen's $58 mil. purchase of Epoch Biosciences adds real-time PCR reagents to the firm's offerings for research institutions and clinical reference labs

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts